This week saw the approval of two new molecular entities by the FDA along with a strong advisory panel recommendation.   Here is my recap of the top regulatory news stories to follow: Valeant Pharmaceuticals has won U.S. FDA approval for its glaucoma drug Vyzulta ending a more than two-year effort to bring the drug to[…]